ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease

INTRODUCTION: Lecanemab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that preferentially targets soluble aggregated Aβ species (protofibrils) with activity at amyloid plaques. Amyloid‐related imaging abnormalities (ARIA) profiles appear to differ for various anti‐amyloid antibodies. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Honig, Lawrence S., Barakos, Jerome, Dhadda, Shobha, Kanekiyo, Michio, Reyderman, Larisa, Irizarry, Michael, Kramer, Lynn D., Swanson, Chad J., Sabbagh, Marwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026083/
https://www.ncbi.nlm.nih.gov/pubmed/36949897
http://dx.doi.org/10.1002/trc2.12377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026083/
https://www.ncbi.nlm.nih.gov/pubmed/36949897
http://dx.doi.org/10.1002/trc2.12377

Ejemplares similares